Multiple sclerosis drug pipeline

Compounds in development

No compounds populated for this indication yet — see registered trials below.

Trials recruiting now (100)

100 drug-interventional multiple sclerosis trials recruiting now, of 1,155 registered interventional trials. Browse all on ClinicalTrials.gov →

• Phase 4Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications

  100% Oxygen

  Jay C. Buckey Jr.n=100Started Aug 2026NCT07240649
• Phase 4A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

  OCR SC

  Genentech, Inc.n=100Puerto Rico, United States · 11 sitesStarted Jul 2026NCT07609719
• Phase 4Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis

  XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector

  Tulane Universityn=20United States · 1 siteStarted Jun 2026NCT04601233
• Phase 4Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

  Silodosin 8 mg, Placebo

  Atlantic Health Systemn=60United States · 1 siteStarted Apr 2026NCT07614321
• Phase 4Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

  Ublituximab, Ocrelizumab

  Johns Hopkins Universityn=50United States · 1 siteStarted Feb 2026NCT07389590
• Phase 4Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

  Ublituximab

  Northwestern Universityn=40United States · 1 siteStarted Nov 2025NCT07225361
• Phase 4A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS)

  Dimethyl Fumarate Enteric-coated Capsules

  Qilu Pharmaceutical (Hainan) Co., Ltd.n=50Started Sep 2025NCT07138833
• Phase 4A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

  Ocrelizumab

  Hoffmann-La Rochen=60China · 17 sitesStarted Jul 2025NCT07483450
• Phase 4Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

  Ocrelizumab

  University of California, San Franciscon=5United States · 1 siteStarted Feb 2025NCT06495593
• Phase 4Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

  Ozanimod

  University of Colorado, Denvern=100United States · 3 sitesStarted Jul 2024NCT06529406
• Phase 4Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

  Dalfampridine 10 MG [Ampyra]

  MGH Institute of Health Professionsn=48United States · 1 siteStarted Jun 2024NCT06136728
• Phase 4Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

  Ocrelizumab, Placebo for Ocrelizumab

  National Institute of Allergy and Infectious Diseases (NIAID)n=123United States · 13 sitesStarted Jan 2023NCT05285891

Showing the 12 most advanced of 100 recruiting drug trials · see all on ClinicalTrials.gov →